Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
The investment will enable the company to enter European markets as well as enhance margins in current markets
To focus on providing safer burn treatments for women and armed forces
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
EC grants conditional marketing authorization based on the EFFISAYIL trial
Subscribe To Our Newsletter & Stay Updated
